Robert W. Baird Issues Positive Forecast for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH) had its price target hoisted by Robert W. Baird from $67.00 to $86.00 in a research note released on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other analysts have also issued reports about the stock. BTIG Research boosted their target price on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. KeyCorp assumed coverage on shares of Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Truist Financial boosted their price target on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 9th. Stifel Nicolaus raised their price objective on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, TD Cowen assumed coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $65.17.

Astrana Health Price Performance

ASTH stock opened at $40.81 on Wednesday. The stock has a market cap of $2.30 billion, a PE ratio of 31.39, a P/E/G ratio of 1.96 and a beta of 1.24. Astrana Health has a 12 month low of $32.04 and a 12 month high of $63.20. The company has a 50-day moving average price of $55.04 and a 200 day moving average price of $47.74. The company has a current ratio of 1.91, a quick ratio of 1.84 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last released its earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. During the same quarter in the prior year, the firm posted $0.47 earnings per share. Equities research analysts anticipate that Astrana Health will post 1.16 earnings per share for the current year.

Hedge Funds Weigh In On Astrana Health

Large investors have recently bought and sold shares of the business. Central Pacific Bank Trust Division purchased a new position in shares of Astrana Health in the 3rd quarter valued at $160,000. SG Americas Securities LLC bought a new position in Astrana Health in the third quarter worth about $680,000. Granite Bay Wealth Management LLC purchased a new stake in shares of Astrana Health during the third quarter valued at about $290,000. Handelsbanken Fonder AB bought a new stake in shares of Astrana Health in the 3rd quarter valued at about $492,000. Finally, GAMMA Investing LLC purchased a new position in shares of Astrana Health in the 3rd quarter worth approximately $34,000. Institutional investors own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.